Horizon Discovery Group, a leading provider of products, services and technologies in the field of genome engineering, has announced the launch of its patient-derived xenograft (PDX) models of breast cancer under its Sage Labs brand. The new panel is the largest available collection of highly characterised PDX models, and is licensed from Washington University.
The collection comprises a broad range of PDX lines, which allow the study of human tumours in an in vivo model system. PDX models are a key tool in the development of personalised medicines. The lines accurately model real patient tumours, enabling researchers to discover important genetic differences, develop biomarkers to distinguish them, and ultimately develop patient-specific therapies.
The new collection includes 10 triple negative lines, as well as several ER+ (estrogen receptor positive) lines. Whole genome sequencing has been performed on the originating tumours, early and late passages of PDX, as well as metastases, demonstrating striking similarity and faithful modelling of the original tumor, with all contaminating mouse signal removed. Using Sage Labs’ PDXplorer, customers can access a wealth of data on the PDX models, including comprehensive patient histories, estradiol responsiveness, RNAseq profiles, DNA microarrays, and phosphoprotein profiles, and can handpick the models that best support their research.
